The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | Minimal residual disease (MRD) monitoring for multiple myeloma is here to stay
Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains that minimal residual disease (MRD) monitoring for multiple myeloma (MM) is here to stay at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He discusses ongoing work to improve and standardize MRD test technologies around the world, and how MRD assays can be used to test depth of response to new therapies and monitor patients to detect relapse early.
